Skip to main content
  • AACR Publications
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

  • Register
  • Log in
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Focus on Computer Resources
    • 75th Anniversary
    • Meeting Abstracts
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • OnlineFirst
    • Editors' Picks
    • Citations
    • Author/Keyword
  • News
    • Cancer Discovery News
  • AACR Publications
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in

Search

  • Advanced search
Cancer Research
Cancer Research

Advanced Search

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Focus on Computer Resources
    • 75th Anniversary
    • Meeting Abstracts
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • OnlineFirst
    • Editors' Picks
    • Citations
    • Author/Keyword
  • News
    • Cancer Discovery News
Cellular and Molecular Biology

Abstract 1056: Galectin-3 induces MUC1 cytoplasmic retention and regulates the EGF-induced EGFR phosphorylation

Johann Merlin, Simon de Beaucé, Laurence Stechly, Anne-Frédérique Dessein-Pouchelle, Isabelle Van Seuningen, Emmanuelle Leteurtre, Guillemette Huet and Pascal Pigny
Johann Merlin
1INSERM, Lille, France.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Simon de Beaucé
1INSERM, Lille, France.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Laurence Stechly
1INSERM, Lille, France.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Anne-Frédérique Dessein-Pouchelle
1INSERM, Lille, France.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Isabelle Van Seuningen
1INSERM, Lille, France.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Emmanuelle Leteurtre
1INSERM, Lille, France.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Guillemette Huet
1INSERM, Lille, France.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Pascal Pigny
1INSERM, Lille, France.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1158/1538-7445.AM10-1056 Published April 2010
  • Article
  • Info & Metrics
Loading
Proceedings: AACR 101st Annual Meeting 2010‐‐ Apr 17‐21, 2010; Washington, DC

Abstract

Pancreatic ductal adenocarcinoma (PDAC) is thought to derive from the epithelial ductal cells of which the apical pole is facing the lumen of the pancreatic ducts. In physiological state, the transmembrane mucin MUC1 is expressed at the apical pole where it protects the cell, senses the environment and modulates signal transduction notably by interacting with EGFR. In tumor cells, the localization of MUC1 glycoprotein is modified. MUC1 expression at the membrane becomes circumferential and accumulates in the cytoplasm. This sequestration is thought to deliver oncogenic signals to the cell, and is used by pathologists on fine-needle aspirates of pancreatic lesions as an indicator of malignancy. However, the mechanisms explaining the modified topography of MUC1 expression in cancer cells are still unknown. Since it was previously demonstrated that endogenous lectins from the galectin family, especially galectin-3 and −4, control the apical targeting of glycoproteins in epithelial cells, our aim was to study the role of galectin-3 in the control of MUC1 expression topography in PDAC, and in the cell invasiveness in vitro. To this end we stably and selectively knocked-down (KD) galectin-3 expression by shRNA approach in the pancreatic polarized CAPAN-1 cells. Three different shRNA targeting LGALS3 mRNA were designed (sh1, sh2, sh3) together with a scramble control one (sc). Sh1 and sh3 cells were selected on the basis of the efficiency of the KD evaluated both at RNA and protein levels. Galectin-3 down-regulation is associated with a decrease of both MUC1 and EGFR protein levels. However, sh1 and sh3 cells expressed 2-fold higher levels of phosphoEGFR in response to EGF treatment than sc cells. The localization of MUC1 and EGFR was studied by confocal microscopy. In sc cells, MUC1 staining mainly concerns the apical surface and the cytoplasm as expected. In sh1 cells, invalidation of galectin-3 led to a strong decrease of MUC1 cytoplasmic labeling. To check the clinical relevance of our data, we performed MUC1 and galectin-3 immunostaining on 16 human PDAC surgically removed in our hospital. In all PDAC, 100% of the tumor cells exhibited a positive and strong MUC1 immunostaining that concerned the cell cytoplasm. By contrast, in normal ductal cells MUC1 staining was restricted to the apical side. Galectin-3 staining was weaker and more heterogeneous than that of MUC1. In all PDAC, 5-80% of the tumor cells were galectin-3 positive with a variable intensity of the immunostaining. Finally, sh1, sh3 and sc cell invasiveness was assessed in vitro on collagen type I matrix. Preliminary results showed that sh1 and sh3 cells lost their in vitro invasive phenotype. In conclusion, our data showed that galectin-3 is responsible for MUC1 cytoplasmic retention in pancreatic tumor cells. Silencing of galectin-3 promotes MUC1 localization at the cell membrane, and increases EGF-induced EGFR phosphorylation.

Note: This abstract was not presented at the AACR 101st Annual Meeting 2010 because the presenter was unable to attend.

Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 1056.

  • ©2010 American Association for Cancer Research
Back to top
Cancer Research: 70 (8 Supplement)
April 2010
Volume 70, Issue 8 Supplement
  • Table of Contents
  • Index by Author

Sign up for alerts

Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Research article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Abstract 1056: Galectin-3 induces MUC1 cytoplasmic retention and regulates the EGF-induced EGFR phosphorylation
(Your Name) has forwarded a page to you from Cancer Research
(Your Name) thought you would be interested in this article in Cancer Research.
Citation Tools
Abstract 1056: Galectin-3 induces MUC1 cytoplasmic retention and regulates the EGF-induced EGFR phosphorylation
Johann Merlin, Simon de Beaucé, Laurence Stechly, Anne-Frédérique Dessein-Pouchelle, Isabelle Van Seuningen, Emmanuelle Leteurtre, Guillemette Huet and Pascal Pigny
Cancer Res April 15 2010 (70) (8 Supplement) 1056; DOI: 10.1158/1538-7445.AM10-1056

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Abstract 1056: Galectin-3 induces MUC1 cytoplasmic retention and regulates the EGF-induced EGFR phosphorylation
Johann Merlin, Simon de Beaucé, Laurence Stechly, Anne-Frédérique Dessein-Pouchelle, Isabelle Van Seuningen, Emmanuelle Leteurtre, Guillemette Huet and Pascal Pigny
Cancer Res April 15 2010 (70) (8 Supplement) 1056; DOI: 10.1158/1538-7445.AM10-1056
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
Advertisement

Related Articles

Cited By...

More in this TOC Section

Cellular and Molecular Biology

  • Abstract SY29-01: Functions of wild type and mutant p53
  • Abstract SY34-02: The impact of O2 availability on human cancer
  • Abstract SY19-01: Cell to cell variability in the responses of tumor cells to death ligands
Show more 3

Poster Presentations - Proffered Abstracts

  • Abstract LB-236: Risk of tMDS/AML after chemotherapy for first primary lymphoid malignancy, 2000-2013
  • Abstract LB-001: Impact of direct physician engagement with racial/ethnic minorities for oncology clinical trial access and accrual model
  • Abstract LB-107: EV-TRACK: transparent reporting and centralizing knowledge of extracellular vesicles to support the validation of extracellular vesicle biomarkers in cancer research
Show more 3

Poster Presentations - Cancer Signaling 1

  • Abstract 1053: Modulation of Wnt/β-catenin signaling pathway by Cripto-1 in mouse embryonal carcinoma F9 cells
  • Abstract 1048: Homogenous, bioluminescent and HTS formatted assay for quantization of ADP production in kinase and ATPase reactions
  • Abstract 1050: CD109 expression promotes cell activity and enhances EGF signaling in human glioblastoma cells
Show more 3
  • Home
  • Alerts
  • Feedback
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians
  • Reviewers

About Cancer Research

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2018 by the American Association for Cancer Research.

Cancer Research Online ISSN: 1538-7445
Cancer Research Print ISSN: 0008-5472
Journal of Cancer Research ISSN: 0099-7013
American Journal of Cancer ISSN: 0099-7374

Advertisement